Home Alzheimer’s Disease Toni Choueiri, MD, on How New Data Impact the Standard of Care...

Toni Choueiri, MD, on How New Data Impact the Standard of Care for RCC

Nivolumab (Opdivo) plus cabozantinib (Cabometyx) demonstrated improved efficacy and prolonged survival compared with sunitinib (Sutent) among patients with previously untreated advanced renal cell carcinoma (RCC), regardless of sarcomatoid status, according to results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium.

In an interview with CancerNetwork®, Toni Choueiri, MD, director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital as well as the Jerome and Nancy Kohlberg Chair and professor of Medicine at Harvard Medical School, discussed how these results may inform the standard-of-care in frontline RCC.

[CheckMate 9ER] is a study that led to the approval of that regimen in the frontline by the FDA in…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments